Lexicon SVP granted RSUs and stock options

Lexicon Pharmaceuticals reported that SVP, Partnerships & Corporate Strategy Rachel Yap Martens received new equity awards on February 12, 2026.

Rhea-AI Filing Summary

Lexicon Pharmaceuticals reported that SVP, Partnerships & Corporate Strategy Rachel Yap Martens received new equity awards on February 12, 2026. She was granted 193,740 restricted stock units, each representing one future share of common stock, and a stock option for 290,620 shares at an exercise price of $1.37 per share.

The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, subject to continued service.

Insider Trade Summary

Grant/Award: 484,360 shares

Grant/Award 2 txns

Insider Martens Rachel Yap

Role SVP, Partnerships & Corp Strat

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	193,740	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	290,620	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 193,740 contracts (Direct); Stock Option (Right to Buy) — 290,620 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. F2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
3. F3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lexicon Pharmaceuticals (LXRX) report for Rachel Yap Martens?

Lexicon Pharmaceuticals reported equity awards to SVP Rachel Yap Martens. She received 193,740 restricted stock units and a stock option for 290,620 common shares, both granted on February 12, 2026, as part of her compensation package.

How many restricted stock units were granted to the Lexicon (LXRX) executive?

Rachel Yap Martens was granted 193,740 restricted stock units. Each unit represents a contingent right to receive one share of Lexicon common stock, subject to a time-based vesting schedule over three years following the grant year.

What are the terms of the stock option granted by Lexicon Pharmaceuticals (LXRX)?

The stock option covers 290,620 shares of common stock at an exercise price of $1.37 per share. It vests 25% on the first anniversary of grant, then 1/48th each month thereafter, contingent on continued service through those dates.

How do the Lexicon (LXRX) restricted stock units for the SVP vest over time?

The restricted stock units vest in three equal installments. One-third of the 193,740 units vest on February 28 of each of the three years following the grant year, assuming the executive continues in service through those vesting dates.

Are the Lexicon (LXRX) equity awards to Rachel Yap Martens directly owned?

Yes. The filing shows both the restricted stock units and the stock option as directly owned by Rachel Yap Martens. The ownership code is listed as “D,” indicating direct beneficial ownership rather than through an indirect entity or trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martens Rachel Yap

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

THE WOODLANDS TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Partnerships & Corp Strat

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/12/2026		A		193,740		(2)	(2)	Common Stock	193,740	$0	193,740	D
Stock Option (Right to Buy)	$1.37	02/12/2026		A		290,620		(3)	02/12/2036	Common Stock	290,620	$0	290,620	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

	/s/ Rachel Y. Martens	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.